Stock Comparison

IVVD vs LLY

Invivyd Inc vs Eli Lilly and Co

The Verdict

IVVD takes this one.

Winner

IVVD

Invivyd Inc

7.5

out of 10

Solid Pick

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$406M

Market Cap

$965.0B

-3.7

P/E Ratio

52.6

-98.2%

Profit Margin

N/A

-67.9%

Return on Equity

N/A

0.0

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

7.5

DVR Score

0.5

The Deep Dive

IVVD7.5/10

Invivyd (IVVD) presents a compelling high-risk, high-reward opportunity, demonstrating significant improvement since our last analysis. The reported Q4 2025 earnings (March 5, 2026) were a major catalyst, showcasing a substantial revenue beat ($17.2M actual vs. $15.77M est.), a 31% sequential growth for PEMGARDA, and a remarkable 110% YoY revenue increase for FY 2025 to $53.4M. Critically, Q4 2025...

Full IVVD Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.